Glioblastoma is a aggressive brain cancer known for its rapid growth and resistance to standard treatments. Research are constantly underway to identify new treatment strategies, and recently, a novel biomarker named LCA168 has emerged as a potential target for glioblastoma treatment. LCA168 is a protein that is highly expressed in GBM cells compa